Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) CFO Daron Evans acquired 5,000 shares of Rezolute stock in a transaction dated Tuesday, June 24th. The shares were bought at an average price of $4.05 per share, for a total transaction of $20,250.00. Following the transaction, the chief financial officer now owns 268,900 shares of the company's stock, valued at approximately $1,089,045. The trade was a 1.89% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Daron Evans also recently made the following trade(s):

• On Wednesday, March 26th, Daron Evans acquired 10,000 shares of Rezolute stock. The shares were bought at an average cost of $2.89 per share, with a total value of $28,900.00.

Rezolute Stock Up 0.8%

RZLT traded up $0.03 on Friday, hitting $4.34. The company had a trading volume of 871,651 shares, compared to its average volume of 619,755. The business's fifty day simple moving average is $3.95 and its 200 day simple moving average is $4.08. Rezolute, Inc. has a 12-month low of $2.22 and a 12-month high of $6.19. The company has a market cap of $371.50 million, a PE ratio of -3.78 and a beta of 1.04.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rezolute

Several hedge funds and other institutional investors have recently made changes to their positions in the company. American Century Companies Inc. grew its holdings in Rezolute by 5.2% during the 1st quarter. American Century Companies Inc. now owns 67,925 shares of the company's stock valued at $197,000 after purchasing an additional 3,334 shares during the last quarter. Pale Fire Capital SE grew its stake in shares of Rezolute by 9.1% during the first quarter. Pale Fire Capital SE now owns 47,122 shares of the company's stock valued at $137,000 after buying an additional 3,935 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Rezolute by 48.5% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock valued at $97,000 after buying an additional 6,470 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after buying an additional 9,000 shares during the period. Finally, Alpine Global Management LLC bought a new stake in shares of Rezolute during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 82.97% of the company's stock.

Analyst Upgrades and Downgrades

RZLT has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of Rezolute in a research note on Monday, April 28th. Wedbush reaffirmed an "outperform" rating and set a $12.00 price objective on shares of Rezolute in a report on Wednesday, May 14th. Finally, Wall Street Zen lowered shares of Rezolute from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $11.83.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.